Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1439]

Investigating anticarcinogenic compounds as an alternative to chemo

Dr Bernardo Bonnani - European Institute of Oncology, Milan, Italy

Investigating anticarcinogenic compounds as an alternative to chemo ( Dr Bernardo Bonnani - European Institute of Oncology, Milan, Italy )

Advances in diagnostic devices in melanoma screening

Dr Alessandro Testori - European Institute of Oncology, Milan, Italy

Advances in diagnostic devices in melanoma screening ( Dr Alessandro Testori - European Institute of Oncology, Milan, Italy )

KRAS/NRAS and BRAF mutations in study of panitumumab plus FOLFIRI for second...

Prof Marc Peeters - University of Antwerp, Antwerp, Belgium

KRAS/NRAS and BRAF mutations in study of panitumumab plus FOLFIRI for second-line treatment of mCC ( Prof Marc Peeters - University of Antwerp, Antwerp, Belgium )

Summary of breaking prostate news from ASCO 2014

Prof Eleni Efstathiou and Prof Gordon McVie

Summary of breaking prostate news from ASCO 2014 ( Prof Eleni Efstathiou and Prof Gordon McVie )

Ipilimumab and nivolumab achieves long-term survival in advanced melanoma

Prof Mario Sznol - Yale Cancer Center, New Haven, USA

Ipilimumab and nivolumab achieves long-term survival in advanced melanoma ( Prof Mario Sznol - Yale Cancer Center, New Haven, USA )

Comment: HPV-targeted adoptive T cell therapy may provide a new strategy for...

Dr Steven O'Day - Beverly Hills Cancer Center, Los Angeles, USA

Comment: HPV-targeted adoptive T cell therapy may provide a new strategy for advanced cervical cancer ( Dr Steven O'Day - Beverly Hills Cancer Center, Los Angeles, USA )

Comment: Adjuvant ipilimumab in high-risk melanoma

Dr Steven O'Day - Beverly Hills Cancer Center, Los Angeles, USA

Comment: Adjuvant ipilimumab in high-risk melanoma ( Dr Steven O'Day - Beverly Hills Cancer Center, Los Angeles, USA )

Comment: Immunotherapy combo increases median survival in advanced melanoma

Dr Steven O'Day - Beverly Hills Cancer Center, Los Angeles, USA

Comment: Immunotherapy combo increases median survival in advanced melanoma ( Dr Steven O'Day - Beverly Hills Cancer Center, Los Angeles, USA )

Success for ipilimumab and nivolumab combo in advanced melanoma

Prof Mario Sznol - Yale Cancer Center, New Haven, USA

Success for ipilimumab and nivolumab combo in advanced melanoma ( Prof Mario Sznol - Yale Cancer Center, New Haven, USA )

Phase III SELECT trial shows lenvatinib to be effective in resistant thyroid...

Prof Martin Schlumberger - Institut Gustave Roussy, Villejuif, France

Phase III SELECT trial shows lenvatinib to be effective in resistant thyroid cancer ( Prof Martin Schlumberger - Institut Gustave Roussy, Villejuif, France )

Blinatumomab shown to be beneficial in relapsed/refractory B-precursor acute...

Prof Max Topp - Würzburg University Hospital, Würzburg, Germany

$Blinatumomab shown to be beneficial in relapsed/refractory B-precursor acute lymphoblastic leukaemia ( Prof Max Topp - Würzburg University Hospital, Würzburg, Germany )$

Regorafenib shows early promise in colorectal candidates unable to undergo chemo

Dr Enrique Grande - Hospital Ramon y Cajal, Madrid, Spain

Regorafenib shows early promise in colorectal candidates unable to undergo chemo ( Dr Enrique Grande - Hospital Ramon y Cajal, Madrid, Spain )

More from ecancer